Observing cancer outcomes in patients receiving integrative oncology care
Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study
This study is testing how well combining naturopathic medicine with regular cancer treatments helps early-stage and advanced-stage cancer patients live longer and stay healthy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Advanced Integrative Medical Science Institute Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT04495790 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate disease-free survival in early-stage cancer patients and overall survival outcomes in advanced-stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment. It will collect data from patients at the AIMS Institute, focusing on the effectiveness of naturopathic medicine integrated with conventional cancer treatments. The study addresses a gap in knowledge regarding the outcomes of patients utilizing complementary and alternative medicine therapies in conjunction with standard oncology care.
Who should consider this trial
Good fit: Ideal candidates include new or established cancer patients receiving treatment at the AIMS Institute who can provide informed consent.
Not a fit: Patients without a cancer diagnosis or those unable to understand the study requirements may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of integrative oncology approaches for improving cancer patient outcomes.
How similar studies have performed: While there have been studies on complementary and alternative medicine in cancer care, this specific approach focusing on naturopathic oncology in an integrative setting is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or 2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute; 3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment; 4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient; 5. A confirmed diagnosis of cancer based on medical oncology medical records. Exclusion Criteria: 1. Patients not diagnosed with cancer; 2. Telehealth patients; 3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires; 4. Unwilling to participate in the AIMS Institute observational study.
Where this trial is running
Seattle, Washington
- AIMS Institute — Seattle, Washington, United States (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.